PTK2 and non-small cell lung carcinoma: Liu et al. (2020) have provided evidence that Brusatol, functioning as an Nrf2 inhibitor, demonstrated inhibitory effects in human NSCLC by instigating ferroptosis through modulation of the FOCAD-FAK signaling pathway.